Publications
5674 Results
- Journal / Conference
- Blood 122:488; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), oral;
- Year
- 2013
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
NUP98/NSD1 translocation further risk-stratifies patients with FLT3/ITD in acute myeloid leukemia: A report from Children’s Oncology Group and SWOG
- Journal / Conference
- Blood 122:1315; American Society of Hematology annual meeting (Dec 7-10, New Orleans, LA), poster;
- Year
- 2013
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106, SWOG-9031, SWOG-9333, SWOG-9500
Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG report
- Journal / Conference
- Nutrients 5(4):1122-1148
- Year
- 2013
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID23552052
- PMC
- PMC3705339
- Study Number(s)
- S0000
Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT)
- Journal / Conference
- Journal of Clinical Oncology 31(3):373-379
- Year
- 2013
- Research Committee(s)
- Melanoma
- PMID
- PMID23248256
- PMC
- PMC4878104
- Study Number(s)
- CTSU/E2603
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
- Journal / Conference
- Journal of Clinical Oncology 31(18):2347-2357
- Year
- 2013
- Research Committee(s)
- Myeloma
- PMID
- PMID23690408
- PMC
- PMC Journal - In process
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease
- Journal / Conference
- Clinical Cancer Research 19(20):5798-5807;
- Year
- 2013
- Research Committee(s)
- Breast
- PMID
- PMID23965903
- PMC
- PMC3805021
- Study Number(s)
- N9831
Impact of c-myc protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831
- Journal / Conference
- Cancer 119(15):2675-2682
- Year
- 2013
- Research Committee(s)
- Breast
- PMID
- PMID23744760
- PMC
- PMC4126833
- Study Number(s)
- N9831
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
- Journal / Conference
- Journal of Clinical Oncology 31(17):2115-2122
- Year
- 2013
- Research Committee(s)
- Breast
- PMID
- PMID23650412
- PMC
- PMC3731983
- Study Number(s)
- N9831
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
- Journal / Conference
- Cancer 119(16):3007-3011
- Year
- 2013
- Research Committee(s)
- Cancer Control
- PMID
- PMID23720006
- PMC
- PMC3735626
- Study Number(s)
- SWOG-9217
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome
- Journal / Conference
- Annals of Surgery 258(3):422-429;
- Year
- 2013
- Research Committee(s)
- Sarcoma
- PMID
- PMID23860199
- PMC
- pending
- Study Number(s)
- CTSU/Z9000